GlassScriptPhysician profile
Karim R Saab
NPI 1366708794
$9,325.43
in general payments reported to CMS, 2019-2025
32 companies · $6,534 in 2025
The $6,534 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $57.58 · 2023: $508 · 2024: $2,214 · 2025: $6,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,450 · Food and Beverage: $2,793 · Education: $12.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,450.00 |
| Food and Beverage | $2,793.03 |
| Education | $12.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,115.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,883.80 | 2025 | |
| Genentech USA, INC. | $1,561.73 | 2022-2025 | Tecentriq, Alecensa |
| Janssen Scientific Affairs, LLC | $1,080.00 | 2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $708.29 | 2022-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $473.80 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Pfizer INC. | $227.54 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $218.24 | 2023-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $145.38 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Array Biopharma INC | $121.92 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Novartis Pharmaceuticals Corporation | $96.07 | 2024-2025 | |
| Celgene Corporation | $88.43 | 2024-2025 | Reblozyl |
| Exelixis INC. | $74.37 | 2023-2025 | Cabometyx |
| Mirati Therapeutics, INC. | $70.78 | 2023-2024 | Krazati |
| Eisai INC. | $66.86 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $61.36 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $58.03 | 2023-2024 | Lynparza, Enhertu |
| Janssen Biotech, INC. | $37.51 | 2023-2024 | Darzalex, Tecvayli, Talvey |
| Myriad Genetic Laboratories, INC. | $36.97 | 2023-2024 | Myrisk |
| Regeneron Healthcare Solutions, INC. | $31.17 | 2024 | Libtayo |
| Tempus Ai, INC | $20.15 | 2024 | Xt Cdx |
| Karyopharm Therapeutics INC. | $18.81 | 2023 | Xpovio |
| Agios Pharmaceuticals, INC. | $18.56 | 2025 | Pyrukynd |
| Lilly USA, LLC | $17.00 | 2023 | Verzenio, Retevmo, Jaypirca |
| Alexion Pharmaceuticals, INC. | $16.96 | 2024 | Ultomiris |
| Amgen INC. | $16.49 | 2023 | Kyprolis |
| Incyte Corporation | $16.42 | 2024 | Opzelura |
| Pharmacosmos Therapeutics INC. | $16.11 | 2024 | Monoferric |
| Galvanize Therapeutics, INC | $15.76 | 2024 | Aliya System |
| Gilead Sciences, INC. | $11.92 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Saab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.